Beta Bionics appoints Beth Brooke to its Board as Independent Director
Concord, MA – December 30, 2020 – Beta Bionics, Inc. — a medical technology company developing the iLet™ the world’s first fully automated bionic pancreas system — today announced that Beth Brooke has been appointed to the Company’s Board of Directors.
We are so pleased to have Beth join our Board of Directors at Beta Bionics. Her fierce commitment to egalitarianism, opportunity, diversity, and innovation is perfectly aligned with the core principles and values of our benefit mission at Beta Bionics,
said Ed Damiano, President and Chief Executive Officer of Beta Bionics.
Throughout her career, Beth has helped shape public health policy through her strategic leadership in both the public and private sectors. This unique experience, combined with her advocacy for diversity and inclusiveness, will be vitally important in guiding our purpose and mission at Beta Bionics, acting in the best possible interest of all people living with type 1 diabetes.
Ms. Brooke serves on the Boards of eHealth, Inc (NASDAQ:EHTH) and other private companies, in addition to the United States Olympic and Paralympic Committee. She is the former Global Vice Chair of Public Policy at Ernst & Young, where she served on its Global Board and as the global sponsor for Diversity and Inclusiveness. In the Clinton Administration, she worked in the U.S. Department of the Treasury and was responsible for tax-policy matters related to healthcare reform, insurance, and managed care.
Additionally, Ms. Brooke has been named by Forbes to its list of 100 Most Powerful Women eleven times, is in the OutStanding LGBT Hall of Fame, and chairs the steering committee of The Partnership for Global LGBTI Equality, in conjunction with the World Economic Forum.
Ms. Brooke received a Bachelor’s of Science degree from Purdue University, graduating with highest distinction while studying Industrial Management and Computer Science and playing women’s intercollegiate basketball. She has received honorary doctorates from Purdue University, Indiana University and Babson College and is in the Indiana Basketball Hall of Fame.
I’m honored to have the opportunity to work with the terrific management team at Beta Bionics to revolutionize the quality of life for so many people dealing with type 1 diabetes and their families. I am also excited to do this as a Certified B corporation, and have the opportunity to govern in accordance with the company’s incredible mission,
said Ms. Brooke.
Ms. Brooke will be serving as Director alongside Ms. Martha Aronson, Mr. Sean Carney, Dr. Finny Kuruvilla from Eventide Asset Management Funds, Mr. Jeff Hitchcock from Children With Diabetes, and Dr. Ed Damiano, President and CEO of Beta Bionics.
About Beta Bionics
Beta Bionics® is a for-profit Massachusetts public benefit corporation founded in 2015 to commercialize the iLet bionic pancreas system. The iLet controls glycemia using integrated mathematical dosing algorithms, which incorporate lifelong autonomous learning to determine and automatically deliver microdoses of insulin and glucagon. These mathematical dosing algorithms were developed in the Damiano Lab at Boston University and refined based on results from home-use clinical trials in adults and children with T1D. Beta Bionics is a Certified B Corporation™ whose founders — in addition to Ed Damiano — include other parents of children with T1D and people with T1D. Beta Bionics is committed to acting in the best interests of the diabetes community and to bringing the iLet to market as expeditiously and responsibly as possible. Beta Bionics is pursuing regulatory clearance of its insulin-only bionic pancreas, followed by its dual-hormone system, which will also administer a glucagon analog in order to raise blood- sugar levels without the need to consume carbohydrates.
Beta Bionics operates in Massachusetts and California. For further information, please visit www.betabionics.com or follow Beta Bionics Facebook, YouTube, Instagram, LinkedIn and Twitter @BetaBionics.
Ed Damiano, PhD
Gibb Clarke, MBA